Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Oric Pharmaceuticals Inc (ORIC)
Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 987,585
  • Shares Outstanding, K 67,366
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,120 K
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.81
Trade ORIC with:

Options Overview Details

View History
  • Implied Volatility 130.51% ( +14.17%)
  • Historical Volatility 87.35%
  • IV Percentile 82%
  • IV Rank 52.14%
  • IV High 234.44% on 10/20/23
  • IV Low 17.30% on 01/02/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 147
  • Volume Avg (30-Day) 95
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 2,305
  • Open Int (30-Day) 4,297

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.49
  • Number of Estimates 5
  • High Estimate -0.47
  • Low Estimate -0.50
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +5.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.96 +47.19%
on 02/22/24
15.38 -4.65%
on 03/01/24
+3.14 (+27.26%)
since 02/01/24
3-Month
7.85 +86.75%
on 01/08/24
15.38 -4.65%
on 03/01/24
+6.39 (+77.27%)
since 12/01/23
52-Week
4.09 +258.44%
on 03/10/23
15.38 -4.65%
on 03/01/24
+10.26 (+233.18%)
since 03/01/23

Most Recent Stories

More News
Why Shares of Oric Pharmaceuticals Jumped Monday

Private investors agreed to spend $85 million to purchase the company's stock.

ORIC : 14.66 (+15.07%)
Pre-Market Brief: Stocks Mixed As Brutal Year Nears End

March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...

ESH23 : 3,957.05s (-0.09%)
META : 502.30 (+2.48%)
AAPL : 179.66 (-0.60%)
SESN : 12.5760 (+7.29%)
HOTH : 1.3400 (+8.94%)
CLLS : 2.65 (+2.71%)
ORIC : 14.66 (+15.07%)
PFE : 26.59 (+0.11%)
TGTX : 17.96 (+4.30%)
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

PFE : 26.59 (+0.11%)
ASLN : 0.7142 (-18.84%)
ORIC : 14.66 (+15.07%)
IMCR : 67.41 (+0.28%)
Pre-Market Brief: Stocks Mostly Lower Ahead of Key U.S. GDP Data

March S&P 500 futures (ESH23) are trending down -0.10% this morning after three major U.S. benchmark indices rallied on Wednesday, notching their biggest one-day percentage gains this month as upbeat corporate...

ESH23 : 3,957.05s (-0.09%)
NKE : 101.88 (-1.62%)
FDX : 246.60 (-0.95%)
ISO : 0.7616 (+2.78%)
MU : 95.15 (+5.01%)
LRCX : 981.53 (+4.61%)
MRTX : 58.70 (-0.17%)
ORIC : 14.66 (+15.07%)
LXRX : 2.48 (-0.40%)
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.

ABBV : 178.91 (+1.62%)
AGLE : 12.01 (+8.79%)
AKRO : 27.81 (+3.04%)
ORIC : 14.66 (+15.07%)
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab

Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.

ACAD : 24.01 (+3.31%)
AGLE : 12.01 (+8.79%)
IMVT : 35.30 (-0.20%)
ORIC : 14.66 (+15.07%)
Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.

GILD : 72.31 (+0.29%)
MGNX : 19.06 (+6.24%)
ACAD : 24.01 (+3.31%)
ORIC : 14.66 (+15.07%)
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce

NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.

ACAD : 24.01 (+3.31%)
AGLE : 12.01 (+8.79%)
NBSE : 0.8950 (+4.07%)
ORIC : 14.66 (+15.07%)
GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults

GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.

GSK : 42.03 (+0.31%)
PFE : 26.59 (+0.11%)
ACAD : 24.01 (+3.31%)
ORIC : 14.66 (+15.07%)
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review

The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.

REGN : 982.82 (+1.73%)
BAYRY : 7.6700 (+1.05%)
ACAD : 24.01 (+3.31%)
ORIC : 14.66 (+15.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 17.47
2nd Resistance Point 16.42
1st Resistance Point 15.54
Last Price 14.66
1st Support Level 13.61
2nd Support Level 12.57
3rd Support Level 11.69

See More

52-Week High 15.38
Last Price 14.66
Fibonacci 61.8% 11.06
Fibonacci 50% 9.73
Fibonacci 38.2% 8.40
52-Week Low 4.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar